Jpmorgan Chase & CO Pyxis Oncology, Inc. Transaction History
Jpmorgan Chase & CO
- $1.22 Trillion
- Q3 2024
A detailed history of Jpmorgan Chase & CO transactions in Pyxis Oncology, Inc. stock. As of the latest transaction made, Jpmorgan Chase & CO holds 21,977 shares of PYXS stock, worth $37,141. This represents 0.0% of its overall portfolio holdings.
Number of Shares
21,977
Previous 21,312
3.12%
Holding current value
$37,141
Previous $70,000
14.29%
% of portfolio
0.0%
Previous 0.0%
Shares
8 transactions
Others Institutions Holding PYXS
# of Institutions
101Shares Held
28.2MCall Options Held
539KPut Options Held
54.1K-
Deep Track Capital, LP Greenwich, CT4.18MShares$7.07 Million0.57% of portfolio
-
Laurion Capital Management LP New York, NY3.63MShares$6.13 Million0.18% of portfolio
-
Black Rock Inc. New York, NY2.79MShares$4.71 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA2.43MShares$4.11 Million0.0% of portfolio
-
Israel Englander Millennium Management LLC | New York, Ny1.91MShares$3.22 Million0.0% of portfolio
About Pyxis Oncology, Inc.
- Ticker PYXS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 35,096,400
- Market Cap $59.3M
- Description
- Pyxis Oncology, Inc., a preclinical stage biopharmaceutical company, engages in the development of therapies to treat cancers. Its immune-oncology product candidates include PYX-106, an investigational fully human immunoglobulin G1 isotype siglec-15 targeting antibody for the treatment of thyroid cancer, head and neck squamous cell carcinoma, no...